JD Health International Inc.
JD Health International Inc. (JDHIF) Financial Performance & Income Statement Overview
Explore the financials of JD Health International Inc. (JDHIF), including yearly and quarterly data on income, cash flow, and balance sheets.
JD Health International Inc. (JDHIF) Income Statement & Financial Overview
Access detailed annual and quarterly income data for JD Health International Inc. JDHIF financial performance.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $29.82B | $28.34B | $26.42B | $13.21B |
| Cost of Revenue | $23.21B | $21.64B | $20.76B | $10.38B |
| Gross Profit | $6.61B | $6.70B | $5.66B | $2.83B |
| Gross Profit Ratio | $0.22 | $0.24 | $0.21 | $0.21 |
| R&D Expenses | $685.42M | $645.01M | $609.63M | $304.82M |
| SG&A Expenses | $5.80B | $5.02B | $5.30B | $2.65B |
| Operating Expenses | $6.48B | $5.66B | $5.91B | $2.90B |
| Total Costs & Expenses | $29.69B | $27.31B | $26.67B | $13.28B |
| Interest Income | $0.00 | $0.00 | $1.01B | $503.74M |
| Interest Expense | $0.00 | $0.00 | $5.10M | $0.00 |
| Depreciation & Amortization | $111.48M | $103.22M | $119.53M | $28.07M |
| EBITDA | $239.37M | $1.14B | -$128.87M | -$96.13M |
| EBITDA Ratio | $0.008 | $0.04 | -$0.005 | -$0.007 |
| Operating Income | $127.89M | $1.04B | -$248.40M | -$124.20M |
| Operating Income Ratio | $0.004 | $0.04 | -$0.009 | -$0.009 |
| Other Income/Expenses (Net) | $2.23B | $1.40B | $679.46M | $555.26M |
| Income Before Tax | $2.36B | $2.44B | $900.68M | $431.06M |
| Income Before Tax Ratio | $0.08 | $0.09 | $0.03 | $0.03 |
| Income Tax Expense | $234.70M | $404.96M | $281.23M | $140.62M |
| Net Income | $2.12B | $2.04B | $580.48M | $290.24M |
| Net Income Ratio | $0.07 | $0.07 | $0.02 | $0.02 |
| EPS | $0.67 | $0.65 | $0.18 | $0.09 |
| Diluted EPS | $0.67 | $0.65 | $0.18 | $0.09 |
| Weighted Avg Shares Outstanding | $3.16B | $3.14B | $3.19B | $3.13B |
| Weighted Avg Shares Outstanding (Diluted) | $3.16B | $3.16B | $3.19B | $3.17B |
Financial performance has remained strong, with revenue growing from $13.21B in Q3 2023 to $29.82B in Q4 2024. Gross profit continued to perform well, with margins at 22% in the latest quarter. Operating income reached $127.89M in Q4 2024, holding a steady 0% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $239.37M. Net income rose to $2.12B, keeping EPS at $0.67. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan